Phaseline

Companies › Atridia

Atridia: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HRS-5041–Phase 1Metastatic Castration Resistant Prostate CancerDec 2026
HRS-6209–Phase 1Breast CancerApr 2027
SHR-1139–Phase 1Psoriasis; Pyoderma Gangrenosum–
SHR-2173–Phase 1Immunology–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07390747SHR-2173Phase 1ImmunologyOtherMay 2026
NCT07078695SHR-1139Phase 1PsoriasisImmunologySep 2026
NCT06830850HRS-5041Phase 1Metastatic Castration Resistant Prostate CancerOncologyDec 2026
NCT07358377HRS-6209Phase 1Breast CancerOncologyApr 2027
NCT07337564SHR-1139Phase 2Pyoderma GangrenosumImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.